Sugi Predict

Sugi Predict / Compounds / Hydroxyhaloperidol

Hydroxyhaloperidol

Hydroxyhaloperidol

SCHEMBL4540106

OC(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 10/20 1.00
▸ DRD3 P35462 6/20 1.00
▸ SIGMAR1 Q99720 4/20 1.00
▸ LMNA P02545 1/20 1.00
▸ CCR1 P32246 3/20 0.74
▸ HTR1A P08908 4/20 0.67
▸ DRD1 P21728 4/20 0.67
▸ DRD5 P21918 4/20 0.67
▸ SLC6A2 P23975 4/20 0.67
▸ HTR2A P28223 4/20 0.67
▸ SLC6A4 P31645 4/20 0.67
▸ HTR7 P34969 4/20 0.67
▸ HRH1 P35367 4/20 0.67
▸ HTR2B P41595 4/20 0.67
▸ SLC6A3 Q01959 2/20 0.65
▸ MEN1 O00255 1/20 0.64
▸ CACNA1F O60840 1/20 0.64
▸ KCNK2 O95069 1/20 0.64
▸ ABCB11 O95342 1/20 0.64
▸ CYP1A2 P05177 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11792972 0.94 DRD2 (0.88) DRD2DRD3SIGMAR1LMNACCR1
SCHEMBL904905 0.91 DRD2 (0.83) DRD2DRD3SIGMAR1LMNACCR1
SCHEMBL10698888 0.88 DRD2 (0.79) DRD2DRD3SIGMAR1LMNACCR1
SCHEMBL11794372 0.88 DRD2 (0.79) DRD2DRD3SIGMAR1LMNACCR1
SCHEMBL11790912 0.88 DRD2 (0.79) DRD2DRD3SIGMAR1LMNACCR1
SCHEMBL11801584 0.88 DRD2 (0.79) DRD2DRD3SIGMAR1LMNACCR1
SCHEMBL11790501 0.88 DRD2 (0.78) DRD2DRD3SIGMAR1LMNACCR1
SCHEMBL9105624 0.85 CCR1 (1.00) DRD2DRD3SIGMAR1LMNACCR1
SCHEMBL11791855 0.85 CCR1 (0.76) DRD2DRD3SIGMAR1LMNACCR1
SCHEMBL11797361 0.85 DRD2 (0.74) DRD2DRD3SIGMAR1LMNACCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3104847-B1 NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) 2020-11-11 — — EP claimed
CN-106456578-B Use of SIGMA-1 receptor agonist compounds 匈牙利科学院大学及其他机构附属研究所 2020-02-18 — — CN claimed
US-20160346290-A1 NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) 2016-12-01 — — US claimed
US-3936468-A PSYCHOTROPIC SUMITOMO CHEMICAL COMPANY, LTD. (JA) 1976-02-03 — — US claimed
US-10842794-B2 Use of Sigma-1 receptor agonist compounds TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) 2020-11-24 — — US disclosed
US-10842794-B2 Use of Sigma-1 receptor agonist compounds TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) 2020-11-24 — — US disclosed
EP-3104847-B1 NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) 2020-11-11 — — EP disclosed
CN-106456578-B Use of SIGMA-1 receptor agonist compounds 匈牙利科学院大学及其他机构附属研究所 2020-02-18 — — CN disclosed
US-20190209575-A1 NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS SigmaDrugs Kft. (HU) 2019-07-11 — — US disclosed
US-20190209575-A1 NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS SigmaDrugs Kft. (HU) 2019-07-11 — — US disclosed
US-10124006-B2 Use of Sigma-1 receptor agonist compounds MTA Tämogatott Kutatócsoportok Irodája (HU) 2018-11-13 — — US disclosed
EP-3104847-A1 NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS Mta Támogatott Kutatócsoportok Irodája (HU) 2016-12-21 — — EP disclosed
CN-103415286-A Compounds and methods for treating pain AKRON MOLECULES GMBH 2013-11-27 — — CN disclosed
US-20130252924-A1 Compounds and Methods for Treating Pain AKRON MOLECULES GMBH (AT) 2013-09-26 — — US disclosed
EP-2637649-A2 COMPOUNDS AND METHODS FOR TREATING PAIN Akron Molecules GmbH (AT) 2013-09-18 — — EP disclosed
WO-2012062925-A2 COMPOUNDS AND METHODS FOR TREATING PAIN AKRON MOLECULES GMBH (AT) 2012-05-18 — — WO disclosed
WO-1996002250-A1 HALOPERIDOL ANALOGS AND THE USE THEREOF ACEA PHARMACEUTICALS INC. (US) 1996-02-01 — — WO disclosed
US-4808630-A MIXTURES OF HALOPERIDOL AND RETINOIC ACID; SCHIZOPHRENIA UNITED STATES OF AMERICA (US) 1989-02-28 — — US disclosed
EP-0279175-A2 Retinoids in the treatment of psychotic illnesses THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) 1988-08-24 — — EP disclosed
US-3936468-A PSYCHOTROPIC SUMITOMO CHEMICAL COMPANY, LTD. (JA) 1976-02-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10124006-B2 Use of Sigma-1 receptor agonist compounds SIGMAR1, TMEM97, OPRL1 DRD2 349/4885DRD3 412/4885SIGMAR1 1/4885
US-20190209575-A1 NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS SIGMAR1, TMEM97, OPRK1 DRD2 361/4885DRD3 456/4885SIGMAR1 1/4885
US-20130252924-A1 Compounds and Methods for Treating Pain TRPV1, ACHE, OPRL1 DRD2 1837/4885DRD3 1629/4885SIGMAR1 492/4885
US-20160346290-A1 NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS SIGMAR1, TMEM97, OPRL1 DRD2 379/4885DRD3 439/4885SIGMAR1 1/4885
US-10842794-B2 Use of Sigma-1 receptor agonist compounds SIGMAR1, TMEM97, OPRK1 DRD2 368/4885DRD3 460/4885SIGMAR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.